-
EP4400171
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4400171
| EP4400171 - USE OF VALBENAZINE FOR TREATING SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.04.2026 Database last updated on 11.04.2026 | |
| Former | Request for examination was made Status updated on 07.03.2025 | ||
| Former | The application has been published Status updated on 14.06.2024 | Most recent event Tooltip | 08.04.2026 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Neurocrine Biosciences, Inc. 6027 Edgewood Bend Court San Diego, CA 92130 / US | [2025/27] |
| Former [2024/29] | For all designated states NEUROCRINE BIOSCIENCES, INC. 12780 El Camino Real San Diego, CA 92130-1102 / US | Inventor(s) | 01 /
O'BRIEN, Christopher, F. San Diego, 92130 / US | 02 /
GRIGORIADIS, Dimitri, E. San Diego, 92130 / US | [2024/29] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2024/29] | Application number, filing date | 24163571.3 | 01.12.2017 | [2024/29] | Priority number, date | US201662429652P | 02.12.2016 Original published format: US 201662429652 P | [2024/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4400171 | Date: | 17.07.2024 | Language: | EN | [2024/29] | Type: | A3 Search report | No.: | EP4400171 | Date: | 11.09.2024 | Language: | EN | [2024/37] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 14.08.2024 | Classification | IPC: | A61K31/4745, A61P25/18 | [2024/37] | CPC: |
A61K31/4745 (EP,US);
A61K9/20 (US);
A61K9/48 (US);
A61P25/18 (EP,US)
|
| Former IPC [2024/29] | A61P25/18 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/29] | Title | German: | VERWENDUNG VON VALBENAZIN ZUR BEHANDLUNG VON SCHIZOPHRENIE ODER SCHIZOAFFEKTIVER STÖRUNG | [2024/29] | English: | USE OF VALBENAZINE FOR TREATING SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER | [2024/29] | French: | UTILISATION DE VALBÉNAZINE POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE OU DU TROUBLE SCHIZOPHAFFICEUX | [2024/29] | Examination procedure | 06.03.2025 | Examination requested [2025/15] | 06.03.2025 | Date on which the examining division has become responsible | 26.03.2025 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 22.05.2025 | Amendment by applicant (claims and/or description) | 07.04.2026 | Despatch of a communication from the examining division (Time limit: M04) | Parent application(s) Tooltip | EP17817594.9 / EP3548027 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 22.05.2025 | Request for further processing filed | 22.05.2025 | Full payment received (date of receipt of payment) Request granted | 28.05.2025 | Decision despatched | Fees paid | Renewal fee | 26.06.2024 | Renewal fee patent year 03 | 26.06.2024 | Renewal fee patent year 04 | 26.06.2024 | Renewal fee patent year 05 | 26.06.2024 | Renewal fee patent year 06 | 26.06.2024 | Renewal fee patent year 07 | 27.12.2024 | Renewal fee patent year 08 | 29.12.2025 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] WO2015120317 (NEUROCRINE BIOSCIENCES INC et al.) | [A] WO2015171802 (NEUROCRINE BIOSCIENCES INC et al.) | [PX] WO2016210180 (NEUROCRINE BIOSCIENCES INC et al.) | [PX] JOSIASSEN RICHARD C ET AL: "Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.", PSYCHOPHARMACOLOGY BULLETIN 01 AUG 2017, vol. 47, no. 3, 1 August 2017 (2017-08-01), pages 61 - 68, XP009503379, ISSN: 0048-5764 | [X] ANONYMOUS: "Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia", NEUROCRINE BIOSCIENCES : INVESTORS : PRESS RELEASE, 9 September 2013 (2013-09-09), XP055197770, Retrieved from the Internet | [X] STEPHEN MARDER ET AL: "KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia", 18 May 2016 (2016-05-18), pages 1, XP055449214, Retrieved from the Internet | [A] BARQUERO ET AL: "Valbenazine for the treatment of tardive dyskinesia", vol. 52, no. 12, 1 December 2016 (2016-12-01), pages 665 - 672, XP093104864, ISSN: 1699-4019, Retrieved from the Internet DOI: http://dx.doi.org/10.1358/dot.2016.52.12.2570977 | UNKNOWN: "INGREZZA - FDA approved Label", 1 April 2017 (2017-04-01), pages 1 - 16, XP055530608, Retrieved from the Internet | by applicant | WO2005077946 | WO2008058261 | EP1716145 | US8039627 | US8357697 | WO2010018408 | WO2011019956 | WO2014047167 | US201615338214 | US8524733 | US4328245 | US4409239 | US4410545 | US6350458 | US3845770 | US3916899 | US3536809 | US3598123 | US4008719 | US5674533 | US5059595 | US5591767 | US5120548 | US5073543 | US5639476 | US5354556 | US5639480 | US5733566 | US5739108 | US5891474 | US5922356 | US5972891 | US5980945 | US5993855 | US6045830 | US6087324 | US6113943 | US6197350 | US6248363 | US6264970 | US6267981 | US6376461 | US6419961 | US6589548 | US6613358 | US6699500 | US5798119 | US5612059 | US5698220 | WO0217918 | US6316652 | US6274552 | US6271359 | US6253872 | US6139865 | US6131570 | US6120751 | US6071495 | US6060082 | US6048736 | US6039975 | US6004534 | US5985307 | US5972366 | US5900252 | US5840674 | US5759542 | US5709874 | KILBOURN ET AL., CHIRALITY, vol. 9, 1997, pages 59 - 62 | MULLER, EXPERT OPIN. INVESTIG. DRUGS, vol. 24, 2015, pages 737 - 742 | LIJINSKY, FOOD COSMET. TOXICOL., vol. 20, 1982, pages 393 | LIJINSKY, J. NAT. CANCER INST., vol. 69, 1982, pages 1127 | MANGOLD, MUTATION RES, vol. 308, 1994, pages 33 | GORDON, DRUG METAB. DISPOS., vol. 15, 1987, pages 589 | ZELLO, METABOLISM, vol. 43, 1994, pages 487 | GATELY, J. NUCL. MED., vol. 27, 1986, pages 388 | WADE D, CHEM. BIOL. INTERACT., vol. 117, 1999, pages 191 | FOSTER ET AL., ADV. DRUG RES., vol. 14, 1985, pages 1 - 36 | KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., vol. 77, 1999, pages 79 - 88 | REMINGTON: "Handbook of Pharmaceutical Excipients", 2012, THE PHARMACEUTICAL PRESS | "Handbook of Pharmaceutical Additives", 2007, GOWER PUBLISHING COMPANY | "Pharmaceutical Preformulation and Formulation", 2009, CRC PRESS LLC | KILBOURN ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, no. 278, 1995, pages 249 - 252 | LEE ET AL., J. MED. CHEM., no. 39, 1996, pages 191 - 196 | SCHERMAN ET AL., JOURNAL OF NEUROCHEMISTRY, vol. 50, no. 4, 1988, pages 1131 - 36 | KILBOURN ET AL., SYNAPSE, vol. 43, no. 3, 2002, pages 188 - 194 | KILBOURN ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 331, no. 2-3, 1997, pages 161 - 68 | ERICKSON ET AL., JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 6, no. 4, 1995, pages 277 - 87 | STANLEY R. KAY: "The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia", SCIZOPHRENIA BULLETIN, vol. 13, 1987, pages 262 - 276 | "Drugs and the Pharmaceutical Science", vol. 126, 2002, MARCEL DEKKER, INC., article "Modifie -Release Drug Delivery Technology" | TAKADA ET AL.: "Encyclopedia of Controlled Drug Delivery", vol. 2, 1999, WILEY | SANTUSBAKER, J. CONTROLLED RELEASE, vol. 35, 1995, pages 1 - 21 | VERMA ET AL., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 26, 2000, pages 695 - 708 | VERMA ET AL., J. CONTROLLED RELEASE, vol. 79, 2002, pages 7 - 27 | DERANGULA ET AL., BIOMEDICAL CHROMATOGRAPHY, vol. 27, no. 6, 2013, pages 792 - 801 | MEHVAR ET AL., DRUG METABOLISM AND DISTRIBUTION, vol. 15, no. 2, 1987, pages 250 - 55 |